Akums Launches Novel Formulations For Patients With Gastrointestinal Disorders

New Delhi: Akums Drugs & Pharmaceuticals Ltd on Monday announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

“Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement.

Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed.

“We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement.

Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Related Posts

Pharma pricing policy threatens innovation

Limited price adjustments have squeezed profitability, say manufacturers Bangladesh: Bangladesh’s pharmaceutical industry is urging the government to review the country’s medicine pricing policy, saying years of limited price adjustments have…

16 empanelled hospitals face action after negligence in Ayushman Scheme

Bijnor: State Agency for Comprehensive Health Insurance Scheme (SACHIS) has initiated action against 16 hospitals after instances of negligence were found. SACHIS, which monitors implementation of Ayushman Bharat Pradhan Mantri…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma pricing policy threatens innovation

Pharma pricing policy threatens innovation

16 empanelled hospitals face action after negligence in Ayushman Scheme

16 empanelled hospitals face action after negligence in Ayushman Scheme

Hollywood fame Bollywood Babe Neetu Chandra emerges a Cancer Crusader worldwide

Hollywood fame Bollywood Babe Neetu Chandra emerges a Cancer Crusader worldwide

18 maternal deaths still a ‘mystery’, says Rajasthan health minister

18 maternal deaths still a ‘mystery’, says Rajasthan health minister

FDA suspends licence of Pune’s Metro Blood Bank; 10 district blood centres face action

FDA suspends licence of Pune’s Metro Blood Bank; 10 district blood centres face action

Health Ministry Unveils Thalassemia Awareness Posters to Promote Early Screening

Health Ministry Unveils Thalassemia Awareness Posters to Promote Early Screening